Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to
RNA Sequencing-Based Platform Will Provide Extensive Genomic Content to Help Inform Surgery and Treatment Decisions for Patients with Suspected Thyroid Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society , suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid
Company to Unveil New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 14, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data will be presented at ENDO 2018, the annual meeting of the Endocrine Society , underscoring the ability of the Afirma
Full-Year Revenue Grew 11%, to $72.0 Million Announces Upcoming Launch of Afirma Xpression Atlas Platform Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results and business
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its fourth quarter and full-year 2017 financial results after the close of market on Tuesday, February 27, 2018 . Following the announcement, Veracyte will host a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 31, 2018-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the LEERINK Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 2:00 p.m.
Milestone Comes During National Thyroid Awareness Month SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 25, 2018-- During National Thyroid Awareness Month in January, Veracyte, Inc. (NASDAQ: VCYT) announced that to date it has performed 100,000 Afirma genomic tests to help reduce unnecessary
Dr. Giulia Kennedy will highlight company's successful use of machine learning to develop genomic diagnostic tests SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that Giulia C. Kennedy , Ph.D., chief science and medical officer, will present at the Precision
55% of participants in national Pulmonary Fibrosis Foundation survey reported at least one misdiagnosis; 61% endured an invasive procedure for diagnosis Authors call for improved physician education, practical clinical guidelines and better diagnostic tools SOUTH SAN FRANCISCO, Calif.
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
